Wholesome Fraction / Learn
Legal 7-OH Alternatives: What Actually Survives August 5, 2026
The durable legal 7-OH alternatives after August 5, 2026 are kratom leaf, mitragynine-based products, and genuinely sub-threshold botanicals (7-OH ≤ 0.05% and ≤ 1.00 mg per article). Products built on mitragynine pseudoindoxyl, MGM-15, or MGM-16 are not alternatives — all three are named in DEA docket DEA-1644 and are scheduled on the same clock as 7-OH itself.
TL;DR
- Survive: kratom leaf, mitragynine-based products, sub-threshold botanicals (proven by COA).
- Scheduled with 7-OH: pseudoindoxyl, MGM-15, MGM-16 — named in DEA-1644 (doc 2026-13581).
- 7-OH itself: DEA-1570 (doc 2026-13580), above 0.05% or 1.00 mg per article.
- Earliest effective date: August 5, 2026; state bans (AL, AR, IN, RI, VT, WI + TN/KS) apply regardless.
The alternatives landscape resets on August 5, 2026. That is the earliest date the DEA's two temporary scheduling orders can take effect — and here is the part most "legal alternative" marketing skips: there are two orders. One covers 7-hydroxymitragynine itself. The other covers mitragynine pseudoindoxyl, MGM-15, and MGM-16 — the exact compounds a large share of "legal 7-OH alternative" products are built on. This guide sorts what genuinely survives the reset from what is scheduled on the same clock as the product it claims to replace.
The two notices, in one paragraph
The DEA signed two notices of intent on July 1, 2026; both published in the Federal Register on July 6, 2026. Document 2026-13580 (Docket No. DEA-1570) places 7-hydroxymitragynine above 0.05% concentration or 1.00 mg per article into temporary Schedule I. Document 2026-13581 (Docket No. DEA-1644) does the same for mitragynine pseudoindoxyl, MGM-15, and MGM-16. The earliest effective date for either is August 5, 2026 — 30 days after publication. Kratom leaf and mitragynine itself are scheduled by neither. We track every date on the live ban status tracker.
Every category, against the notices
| Compound / category | Named in a DEA notice? | Status after Aug 5 |
|---|---|---|
| 7-OH tablets, gummies, shots, isolate | Yes — 2026-13580 (Docket DEA-1570), above 0.05% or 1.00 mg per article | Temporary Schedule I once a final order takes effect (Aug 5, 2026 earliest) |
| Mitragynine pseudoindoxyl ("pseudo") | Yes — 2026-13581 (Docket DEA-1644) | Same timeline as 7-OH — scheduled in the companion order |
| MGM-15 and MGM-16 products | Yes — 2026-13581 (Docket DEA-1644) | Same timeline as 7-OH — scheduled in the companion order |
| Kratom leaf powder, crushed leaf, leaf capsules | No — neither notice | Federally lawful; governed by state kratom law |
| Mitragynine-based extracts and tablets | No — mitragynine is not scheduled by either notice | Federally lawful; governed by state kratom law |
| Sub-threshold botanical products (≤0.05% / ≤1.00 mg 7-OH per article) | Below the DEA-1570 threshold by definition | Outside Schedule I — the COA is what proves the numbers |
Docket texts control. "After Aug 5" assumes final orders issue on or after the earliest effective date; the DEA can also act later or not at all.
The trap category: rebrands named in DEA-1644
Many products currently marketed as "legal 7-OH alternatives" — "pseudo" tablets, MGM-15 and MGM-16 formulations — are built on chemistry that appears, by name, in the DEA's companion notice. There is no threshold to argue about and no interpretive gray zone: the compounds are listed, and they ride the same 30-day clock as 7-OH. A vendor calling them "the legal successor" is either unaware of the notice they are supposedly responding to or counting on you being unaware of it. Before buying anything sold as an alternative, check the named active ingredient against Docket DEA-1644. If it's in there, you are looking at the same regulatory exposure with a new sticker.
What are the legal 7-OH alternatives? The three durable categories
1. Kratom leaf and whole-plant products
Plain leaf powder, crushed leaf, and leaf capsules are the least ambiguous survivors. Raw kratom leaf runs roughly 1–2% mitragynine by dry weight, with 7-hydroxymitragynine present only in trace amounts — naturally below the DEA-1570 threshold. Neither notice touches leaf, so this category's federal status doesn't change on August 5 either way. It remains governed by state kratom law: outright bans in a handful of states, Kratom Consumer Protection Acts in others. The chemistry gap between a whole botanical and a concentrated single alkaloid is the subject of our leaf vs 7-OH primer.
2. Mitragynine-based products
Mitragynine — the primary kratom alkaloid — is not scheduled by either notice, which makes mitragynine-standardized extracts, tablets, and shots the most direct format-for-format continuation of the category. The compliance question for these products is entirely about what else is in them: a mitragynine extract with added or enriched 7-OH above the threshold is a 7-OH product under DEA-1570 no matter what the front label leads with. That makes the alkaloid panel on the COA — not the marketing name — the document that decides what a product is. Retailers that already publish batch-matched lab work for their mitragynine lines, such as Favor'd Alkz, give you the number to check; a brand that won't quantify 7-OH on its COA is asking you to take the legal status on faith.
3. Sub-threshold botanical products
The DEA-1570 threshold — 0.05% concentration or 1.00 mg per article — creates a defined lane for botanical products whose naturally occurring 7-OH sits below both numbers. Full-spectrum leaf extracts and "leaf-ratio" formulations can legitimately occupy it. But the lane is drawn in laboratory numbers, not label adjectives: "compliant," "leaf-ratio," or "full-spectrum" on a package is a marketing sentence until a batch-specific certificate of analysis quantifies 7-OH below the line. Strong extracts are the edge case to watch — concentrating a whole leaf concentrates its trace 7-OH along with everything else, and a product that crosses 0.05% is inside Schedule I regardless of intent.
The buyer checklist for any "alternative"
Four checks, in order, before any product marketed as a legal 7-OH alternative:
- A named compound with a per-unit amount. If you cannot read the specific alkaloid and its milligrams off the label, you cannot evaluate the product against either docket. "Proprietary blend" is a full stop.
- The compound checked against both notices. 7-hydroxymitragynine above threshold (DEA-1570) and pseudoindoxyl/MGM-15/MGM-16 (DEA-1644) are in. Mitragynine and leaf are out. Thirty seconds with the docket answers what the marketing blurs.
- A batch-matched COA from an ISO/IEC 17025-accredited lab — with a lot number that matches the unit in your hand and an alkaloid panel that quantifies 7-OH, not just mitragynine. That number is the only proof of sub-threshold status. Our lab-report guide covers how to verify the accreditation and read the panel.
- Label-vs-lab match and basic compliance signals — the labeled milligrams agree with the COA, the vendor gates at 21+, and restricted states are blocked at checkout. The full nine-point version of this vetting is in the quality checklist.
The state layer still applies
Nothing about the federal reset overrides state law. As of July 2026, Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin prohibit 7-OH products; Tennessee and Kansas restrictions took effect July 1, 2026; Mississippi allows sales to adults 21+ except in 11 northeast counties. Several of those states restrict kratom broadly, which reaches the durable categories too. Check the state-by-state guide before shipping anything.
Frequently asked questions
What is a legal alternative to 7-OH tablets?
After August 5, 2026 — the earliest date the DEA’s temporary scheduling orders can take effect — the durable categories are: traditional kratom leaf products (powder and capsules), mitragynine-based products (mitragynine is not scheduled by either DEA notice), and sub-threshold botanical products that keep 7-hydroxymitragynine at or below 0.05% concentration and 1.00 mg per article. Products built on mitragynine pseudoindoxyl, MGM-15, or MGM-16 are not legal alternatives — all three are named in DEA docket DEA-1644 and are scheduled on the same timeline as 7-OH itself.
Are MGM-15 and MGM-16 legal 7-OH substitutes?
No. MGM-15, MGM-16, and mitragynine pseudoindoxyl are named directly in the DEA’s companion notice of intent (Federal Register document 2026-13581, Docket DEA-1644), published July 6, 2026 alongside the 7-OH notice. If final orders issue, they become temporary Schedule I on the same clock as 7-hydroxymitragynine. Marketing them as "the legal alternative" renames the regulatory exposure; it does not avoid it.
Is mitragynine banned by the DEA notices?
No. Neither notice schedules mitragynine, the primary kratom alkaloid, or kratom leaf itself. Mitragynine-based products with no added or concentrated 7-OH remain outside both federal actions and continue to be governed by state kratom laws — which ban kratom outright in some states and regulate it through consumer protection acts in others.
What does the 0.05% / 1.00 mg threshold mean?
The 7-OH notice (2026-13580, Docket DEA-1570) places 7-hydroxymitragynine into temporary Schedule I only above a threshold: more than 0.05% concentration or more than 1.00 mg per article. Naturally occurring trace 7-OH below those levels in botanical kratom material stays outside Schedule I. For any product claiming sub-threshold status, the only proof is a batch-matched certificate of analysis that quantifies 7-OH — a label claim alone verifies nothing.
Is 7-OH still legal to buy right now?
Federally, yes — as of mid-July 2026, no scheduling order is in effect, and August 5, 2026 is the earliest a temporary order could take effect. At the state level, 7-OH products are banned in Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin; Tennessee and Kansas restrictions took effect July 1, 2026; and Mississippi allows sales to adults 21+ except in 11 northeast counties.
The bottom line
"Legal alternative" is a marketing phrase; the dockets are the category definitions. Three product types survive the August 5 reset: kratom leaf, mitragynine-based products, and genuinely sub-threshold botanicals. The heavily promoted fourth type — pseudoindoxyl and MGM-15/16 products — is named in DEA-1644 and scheduled on the same timeline as 7-OH itself. The label tells you which one you're holding only if it names the compound; the COA tells you whether the label is honest. Check both, then check your state.